Nanotechnology Now - Press Release: Nano-Enabled Paper Detects Kidney Cancer Markers

Home > Press > Nano-Enabled Paper Detects Kidney Cancer Markers

Abstract:
Using common laboratory filter paper coated with antibody-labeled gold nanorods, a team of investigators at Washington University in St. Louis has developed a rapid and inexpensive method for detecting biomarkers of kidney cancer in urine. Srikanth Singamaneni and his collaborators published their findings in the journal Analytical Chemistry.

Nano-Enabled Paper Detects Kidney Cancer Markers

Bethesda, MD | Posted on December 17th, 2012

Kidney cancer, which accounts for three percent of all adult cancers, is a silent killer. It presents with few symptoms until it has spread throughout the body, at which point the disease is largely fatal. In the few instances where a kidney tumor is discovered at an early stage, usually during an abdominal scan for other reasons, surgical removal of the tumor is nearly 100 percent effective at curing this disease.

In 2010, two of Dr. Singamaneni's colleagues at Washington University, Evan Kharasch and Jeremiah Morrissey, led a team that identified two candidate biomarkers for kidney cancer. These molecules, aquaporin-1 and adipophilin, are present in urine at elevated levels in patients with the most common forms of kidney cancer. In addition, the levels of these two proteins correlated with tumor size and fell by as much as 97 percent when tumors were removed surgically.

Urine-based tests have the potential to be used in routine screening efforts but only if they are inexpensive to perform. The technology now used clinically to detect specific proteins such as these two potential biomarkers, known as an enzyme-linked immunosorbent assay (ELISA), is both expensive and time-consuming, and requires a relatively high level of laboratory expertise to produce accurate results.

To solve this problem, Dr. Singamaneni and his colleagues created what they are calling bioplasmonic paper - filter paper impregnated with gold nanorods linked to antibodies that would bind to aquaporin-1. Gold nanorods respond to light by producing what is known as a localized surface plasmon resonance (LSPR), a specific type of light emission that involves waves of electrons moving across the surface of metal nanostructures. LSPR is very sensitive to molecular events that occur on or near the surface of the particles, including binding of biomolecules to attached antibodies.

Traditionally, LSPR detection devices are rigid, flat surfaces such as glass, but Dr. Singamaneni has shown that standard filter paper can also serve as an LSPR substrate. In fact, his team demonstrated that the sensitivity and limit of detection for their paper-based system is at least as good, if not better, than for conventional rigid substrates. In this case, the limit of detection matched that of the range of aquaporin-1 levels in patients with kidney cancer. Other advantages of using paper include its wicking properties, flexible surface for collection, compatibility with standard ink jet printing technology, low cost, and ease of disposal.

####

About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
cancer.nano@mail.nih.gov

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: